18F vipivotide tetraxetan

N/A

Report date: 2025/11/19 17:58:23

NME

Base Information

Drug Name18F vipivotide tetraxetan

Drug Alias Name18F-PSMA-617Al18F-PSMA-617

ClassificationRadiation-emitting products > Nuclides > Fluorine > 18FRadiation-emitting products > Radionuclide Drug ConjugatesRadiation-emitting products > Radioactive diagnostic agent +[4]

Mechanisms of ActionProstate-Specific Membrane Antigen inhibitorsPositron-emission tomography enhancersIonising radiation emitters

TargetsProstate-Specific Membrane Antigen

Therapy Area/IndicationsProstatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaPhase 3 Clinical

Originator CompaniesPeking Union Medical College Hospital

China Registration ClassN/A

Develop Information

Active CompaniesPeking Union Medical College Hospital

Inactive CompaniesN/A

Active IndicationsProstatic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A